GridAI Technologies (GRDX)
Market Price (8/9/2026): $2.76 | Market Cap: $12.3 MilSector: Health Care | Industry: Biotechnology
GridAI Technologies (GRDX)
Market Price (8/9/2026): $2.76Market Cap: $12.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Artificial Intelligence, and Smart Grids & Grid Modernization. Themes include AI Software Platforms, Edge AI, Show more. | Weak multi-year price returns2Y Excs Rtn is -2.8%, 3Y Excs Rtn is -163% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13264% Expensive valuation multiplesP/SPrice/Sales ratio is 164x Stock price has recently run up significantly12M Rtn12 month market price return is 150% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1983% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -8959%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8959% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 80% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -76% High stock price volatilityVol 12M is 152% Key risksGRDX key risks include [1] internal governance friction following recent director resignations, Show more. |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, and Smart Grids & Grid Modernization. Themes include AI Software Platforms, Edge AI, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -2.8%, 3Y Excs Rtn is -163% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13264% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 164x |
| Stock price has recently run up significantly12M Rtn12 month market price return is 150% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1983% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -8959%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8959% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 80% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -76% |
| High stock price volatilityVol 12M is 152% |
| Key risksGRDX key risks include [1] internal governance friction following recent director resignations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
GridAI Technologies (GRDX) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Strong Market Interest in AI Infrastructure. GridAI Technologies (GRDX) experienced a 10.51% surge in its stock on May 29, 2026, driven by renewed investor interest in energy-efficient computing solutions. This positive movement was attributed to the company's specific focus on sustainable AI data center technology within the broader AI and grid infrastructure sector.
2. Positive Broader AI Sector Momentum. The second fiscal quarter of 2026, which ended on June 30, 2026, demonstrated robust activity in the artificial intelligence sector, with AI companies capturing over 70% of all global venture funding during this period. This overall strong market enthusiasm for AI technologies likely contributed to positive sentiment for GridAI Technologies, particularly given its AI-focused subsidiary.
Show more
GridAI Technologies (GRDX) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Strong Market Interest in AI Infrastructure. GridAI Technologies (GRDX) experienced a 10.51% surge in its stock on May 29, 2026, driven by renewed investor interest in energy-efficient computing solutions. This positive movement was attributed to the company's specific focus on sustainable AI data center technology within the broader AI and grid infrastructure sector.
2. Positive Broader AI Sector Momentum. The second fiscal quarter of 2026, which ended on June 30, 2026, demonstrated robust activity in the artificial intelligence sector, with AI companies capturing over 70% of all global venture funding during this period. This overall strong market enthusiasm for AI technologies likely contributed to positive sentiment for GridAI Technologies, particularly given its AI-focused subsidiary.
3. Anticipation of Future Growth and Contracts. The bullish momentum observed in May 2026 was influenced by market participants pricing in potential contract wins or favorable industry reports related to GridAI's advanced AI energy management systems. Management expectations for growing demand for its predictive analytics platform, especially with the increasing need for grid resilience and renewable energy integration, fueled this forward-looking optimism.
4. Narrowing Fiscal Q1 2026 Losses. GridAI Technologies reported its fiscal Q1 2026 earnings on July 7, 2026 (for the quarter ending March 31, 2026), showing a narrowing loss per share of -$0.82. Although revenue figures were not disclosed, this improvement in cost discipline amid market volatility was met with a 1.14% increase in the stock, indicating cautious optimism among investors.
Show less
Stock Movement Drivers
Fundamental Drivers
The 9.2% change in GRDX stock from 4/30/2026 to 8/8/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.51 | 2.74 | 9.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 163.8 | |
| Shares Outstanding (Mil) | 2 | 4 | -62.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| GRDX | 9.2% | |
| Market (SPY) | 7.6% | 22.6% |
| Sector (XLV) | 13.5% | -8.5% |
Fundamental Drivers
The -12.5% change in GRDX stock from 1/31/2026 to 8/8/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.13 | 2.74 | -12.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 163.8 | |
| Shares Outstanding (Mil) | 2 | 4 | -62.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| GRDX | -12.5% | |
| Market (SPY) | 12.1% | 21.3% |
| Sector (XLV) | 7.5% | 2.5% |
Fundamental Drivers
The 107.6% change in GRDX stock from 7/31/2025 to 8/8/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.32 | 2.74 | 107.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 163.8 | |
| Shares Outstanding (Mil) | 2 | 4 | -64.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 8/8/2026| Return | Correlation | |
|---|---|---|
| GRDX | 107.6% | |
| Market (SPY) | 23.4% | 12.6% |
| Sector (XLV) | 28.7% | -2.2% |
Fundamental Drivers
The -91.7% change in GRDX stock from 7/31/2023 to 8/8/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 7312023 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 32.84 | 2.74 | -91.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 163.8 | |
| Shares Outstanding (Mil) | 0 | 4 | -99.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2023 to 8/8/2026| Return | Correlation | |
|---|---|---|
| GRDX | -91.7% | |
| Market (SPY) | 74.9% | 4.6% |
| Sector (XLV) | 29.3% | 1.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GRDX Return | -85% | -98% | -97% | -85% | 150% | -38% | -100% |
| Peers Return | 52% | -31% | 92% | 61% | 33% | 7% | 357% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| GRDX Win Rate | 17% | 8% | 8% | 42% | 42% | 25% | |
| Peers Win Rate | 65% | 33% | 72% | 70% | 55% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| GRDX Max Drawdown | -94% | -99% | -98% | -97% | -64% | -62% | |
| Peers Max Drawdown | -15% | -42% | -17% | -20% | -28% | -25% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MSFT, GOOGL, AMZN, NVDA, IBM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/7/2026 (YTD)
How Low Can It Go
| Event | GRDX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -33.2% | -18.8% |
| % Gain to Breakeven | 49.8% | 23.1% |
| Time to Breakeven | 37 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -78.6% | -7.8% |
| % Gain to Breakeven | 367.0% | 8.5% |
| Time to Breakeven | 403 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.4% | -33.7% |
| % Gain to Breakeven | 93.8% | 50.9% |
| Time to Breakeven | 85 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -61.4% | -19.2% |
| % Gain to Breakeven | 159.0% | 23.8% |
| Time to Breakeven | 135 days | 105 days |
In The Past
GridAI Technologies's stock fell -33.2% during the 2025 US Tariff Shock. Such a loss loss requires a 49.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | GRDX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -33.2% | -18.8% |
| % Gain to Breakeven | 49.8% | 23.1% |
| Time to Breakeven | 37 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -78.6% | -7.8% |
| % Gain to Breakeven | 367.0% | 8.5% |
| Time to Breakeven | 403 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.4% | -33.7% |
| % Gain to Breakeven | 93.8% | 50.9% |
| Time to Breakeven | 85 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -61.4% | -19.2% |
| % Gain to Breakeven | 159.0% | 23.8% |
| Time to Breakeven | 135 days | 105 days |
In The Past
GridAI Technologies's stock fell -33.2% during the 2025 US Tariff Shock. Such a loss loss requires a 49.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About GridAI Technologies (GRDX)
Entero Therapeutics, Inc. (GRDX) is a clinical-stage biopharmaceutical company dedicated to developing innovative, targeted, and orally delivered therapies for a variety of gastrointestinal diseases. The company focuses on addressing significant unmet medical needs within this therapeutic area by advancing its pipeline of novel drug candidates.
The company's robust product pipeline features several key candidates undergoing clinical trials. Latiglutenase, a targeted oral biotherapeutic, is in Phase 2 studies for celiac disease, specifically designed to break down gluten into non-immunogenic peptides. Another candidate, capeserod, a selective 5-HT4 receptor partial agonist, is under Phase 1 studies for the treatment of gastroparesis. Entero Therapeutics is also developing adrulipase, a recombinant lipase enzyme in Phase 2 studies, aimed at improving the digestion of fats and other nutrients for patients with exocrine pancreatic insufficiency caused by cystic fibrosis or chronic pancreatitis. Furthermore, niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, is in Phase 2 studies for conditions such as ulcerative proctitis, ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
In summary, Entero Therapeutics, Inc. targets specialized patient populations suffering from various complex gastrointestinal conditions. Through its diversified pipeline, the company aims to provide new and effective treatment options by advancing its therapies through different stages of clinical development.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
The key risks for GridAI Technologies (GRDX) are primarily associated with the inherent challenges of its diversified business model, encompassing both late clinical-stage biopharmaceutical development and a new venture into AI-driven energy orchestration software.
- Clinical Development and Regulatory Approval Risk: As a late clinical-stage biopharmaceutical company, GridAI Technologies faces substantial risks associated with the development of its pipeline candidates, including latiglutenase, capeserod, adrulipase, and niclosamide. The high failure rate of clinical trials means that these candidates may not prove to be safe or effective, or may experience significant delays or unexpected adverse events. Failure to successfully complete clinical trials or obtain necessary regulatory approvals from health authorities would prevent the company from bringing its therapies to market, significantly impacting its financial viability and future prospects.
- Market Adoption and Competitive Risk in AI/Energy Sector: GridAI Technologies' recent diversification into AI-native energy-orchestration software introduces risks related to market acceptance and intense competition. The company's platform aims to coordinate grid power and manage energy systems for hyperscale AI campuses and distributed energy, a rapidly evolving and competitive market. There is a risk that the company's technology may not achieve sufficient market adoption, or that existing or new competitors could offer superior or more cost-effective solutions, limiting GridAI Technologies' ability to generate substantial revenue from this new segment.
- Funding and Commercialization Risk: Both the biopharmaceutical development and the scaling of a new AI/energy software platform are capital-intensive endeavors. GridAI Technologies currently operates with a relatively small market capitalization and negative EBITDA, indicating a reliance on external financing to fund ongoing operations, clinical trials, and technological development. The inability to secure adequate funding in the future, or challenges in successfully commercializing its products and software even if approved or adopted, could severely constrain the company's growth and operational continuity.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for GridAI Technologies (GRDX) over the next 2-3 years:
- Addressing Hyperscale AI Data Center Energy Demand: GridAI Technologies is positioned to capitalize on the rapidly increasing electricity consumption and complex energy management needs of hyperscale AI data centers. The company develops grid and power-management software aimed at these campuses, providing an AI-driven energy orchestration platform that optimizes energy usage, manages grid connections, and coordinates distributed energy resources. With AI data centers projected to drive significant incremental power demand in the coming years, the demand for GridAI's solutions in this sector is a key revenue driver.
- Expansion and Adoption of the AI-Driven Energy Orchestration Platform: The company's core technology, an AI-driven software and control platform, enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems, on-site generation, and renewables. As the energy landscape becomes more complex due to electrification and distributed energy resources, the increased adoption of this platform by a broader range of customers, seeking to improve efficiency, reduce costs, and participate in grid services markets, is expected to drive revenue growth.
- Continued Advancement of Biopharmaceutical Pipeline: Despite its expanded focus on AI and energy infrastructure, GridAI Technologies (formerly Entero Therapeutics, Inc.) continues to advance its late clinical-stage biopharmaceutical programs targeting gastrointestinal diseases. The company's pipeline includes candidates such as latiglutenase for celiac disease (Phase 2), capeserod for gastroparesis (Phase 1), adrulipase for exocrine pancreatic insufficiency (Phase 2), and niclosamide for ulcerative proctitis/proctosigmoiditis and immune checkpoint inhibitor-associated colitis/diarrhea (Phase 2). Successful progression through clinical trials and potential commercialization of these therapeutic candidates represent significant future revenue opportunities.
AI Analysis | Feedback
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 255.88 |
| Mkt Cap | 3,334.4 |
| Rev LTM | 292,665 |
| Op Inc LTM | 120,670 |
| FCF LTM | 33,208 |
| FCF 3Y Avg | 38,497 |
| CFO LTM | 143,526 |
| CFO 3Y Avg | 105,470 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 17.8% |
| Rev Chg 3Y Avg | 15.5% |
| Rev Chg Q | 19.6% |
| QoQ Delta Rev Chg LTM | 5.0% |
| Op Inc Chg LTM | 21.2% |
| Op Inc Chg 3Y Avg | 23.1% |
| Op Mgn LTM | 25.7% |
| Op Mgn 3Y Avg | 31.9% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 31.6% |
| CFO/Rev 3Y Avg | 36.5% |
| FCF/Rev LTM | 15.5% |
| FCF/Rev 3Y Avg | 18.9% |
Segment Financials
Revenue by Segment| $ Mil | 2025 |
|---|---|
| Grid AI Corp (artificial intelligence (AI Segment)) | 0 |
| GridAI Technologies Corp (gastrointestinal therapies (GI Segment)) | 0 |
| Total | 0 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Grid AI Corp (artificial intelligence (AI Segment)) | -3 | |
| GridAI Technologies Corp (gastrointestinal therapies (GI Segment)) | -4 | |
| Research and development | -2 | |
| Total | -7 | -2 |
| $ Mil | 2025 |
|---|---|
| Grid AI Corp (artificial intelligence (AI Segment)) | -1 |
| GridAI Technologies Corp (gastrointestinal therapies (GI Segment)) | -5 |
| Total | -7 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Research and development | 85 | ||||
| Single segment | 7 | 5 | 12 | 13 | |
| Total | 85 | 7 | 5 | 12 | 13 |
Price Behavior
| Market Price | $2.74 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/11/2016 | |
| Distance from 52W High | -59.7% | |
| 50 Days | 200 Days | |
| DMA Price | $4.39 | $3.37 |
| DMA Trend | down | up |
| Distance from DMA | -37.5% | -18.8% |
| 3M | 1YR | |
| Volatility | 117.4% | 151.7% |
| Downside Capture | 388.18 | 64.90 |
| Upside Capture | 217.79 | 155.25 |
| Correlation (SPY) | 23.8% | 12.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 5.95 | 2.44 | 2.52 | 1.96 | 1.61 | 0.47 |
| Up Beta | 10.63 | 2.27 | 1.15 | 0.24 | 0.93 | -0.07 |
| Down Beta | 1.44 | -1.07 | 0.13 | 0.37 | 3.27 | 0.72 |
| Up Capture | 239% | 174% | 521% | 444% | 242% | 2% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 7 | 17 | 32 | 55 | 117 | 328 |
| Down Capture | 750% | 402% | 294% | 220% | 102% | 105% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 15 | 26 | 31 | 68 | 132 | 413 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRDX | |
|---|---|---|---|---|
| GRDX | 108.2% | 151.7% | 1.15 | - |
| Sector ETF (XLV) | 28.7% | 15.5% | 1.42 | -1.9% |
| Equity (SPY) | 23.3% | 12.8% | 1.36 | 12.0% |
| Gold (GLD) | 28.5% | 28.4% | 0.87 | 2.4% |
| Commodities (DBC) | 32.9% | 19.8% | 1.32 | -8.0% |
| Real Estate (VNQ) | 14.2% | 13.8% | 0.72 | -7.9% |
| Bitcoin (BTCUSD) | -43.7% | 43.0% | -1.21 | 11.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRDX | |
|---|---|---|---|---|
| GRDX | -86.8% | 140.8% | -0.78 | - |
| Sector ETF (XLV) | 6.2% | 15.0% | 0.23 | 2.8% |
| Equity (SPY) | 13.5% | 17.2% | 0.61 | 7.8% |
| Gold (GLD) | 18.6% | 18.6% | 0.81 | -1.7% |
| Commodities (DBC) | 8.2% | 19.6% | 0.31 | -1.4% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 3.5% |
| Bitcoin (BTCUSD) | 9.0% | 53.0% | 0.36 | 3.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRDX | |
|---|---|---|---|---|
| GRDX | -70.9% | 118.5% | -0.51 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 6.5% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 10.2% |
| Gold (GLD) | 12.1% | 16.2% | 0.61 | -1.0% |
| Commodities (DBC) | 7.4% | 18.0% | 0.33 | 2.2% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.20 | 5.9% |
| Bitcoin (BTCUSD) | 58.4% | 66.2% | 0.98 | 3.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/27/2026 | 10-Q |
| 12/31/2025 | 05/01/2026 | 10-K |
| 09/30/2025 | 11/19/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/01/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 10/21/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/20/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/27/2026 | 10-Q |
| 12/31/2025 | 05/01/2026 | 10-K |
| 09/30/2025 | 11/19/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/01/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 10/21/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/20/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/23/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/16/2021 | 10-Q |
| 03/31/2021 | 05/24/2021 | 10-Q |
| 12/31/2020 | 03/31/2021 | 10-K |
| 09/30/2020 | 11/16/2020 | 10-Q |
| 06/30/2020 | 08/14/2020 | 10-Q |
| 03/31/2020 | 05/15/2020 | 10-Q |
| 12/31/2019 | 03/30/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
| 06/30/2019 | 08/13/2019 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.